Page last updated: 2024-11-05

tranexamic acid and Hematologic Malignancies

tranexamic acid has been researched along with Hematologic Malignancies in 5 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders."9.30The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019)
"This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders."5.30The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019)
"Among patients with hematologic malignancy undergoing chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment with TXA compared with placebo did not significantly reduce the risk of WHO grade ≥2 bleeding."3.11Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. ( Boyiadzis, M; Brown, SP; El Kassar, N; Emerson, S; Gernsheimer, TB; Herren, H; Key, NS; May, S; Pagano, MB; Poston, JN; Reeves, BN; Selukar, S; Triulzi, DJ, 2022)
"The most robust data for the treatment of menorrhagia are for tranexamic acid."2.47Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. ( Bates, JS; Buie, LW; Woodis, CB, 2011)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Gernsheimer, TB1
Brown, SP1
Triulzi, DJ1
Key, NS1
El Kassar, N1
Herren, H1
Poston, JN1
Boyiadzis, M1
Reeves, BN1
Selukar, S1
Pagano, MB1
Emerson, S1
May, S1
Zwicker, JI1
Estcourt, LJ1
McQuilten, Z1
Powter, G1
Dyer, C1
Curnow, E1
Wood, EM1
Stanworth, SJ2
Bates, JS1
Buie, LW1
Woodis, CB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia[NCT03136445]Phase 3616 participants (Actual)Interventional2015-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for tranexamic acid and Hematologic Malignancies

ArticleYear
Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy.
    Pharmacotherapy, 2011, Volume: 31, Issue:11

    Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Meno

2011

Trials

2 trials available for tranexamic acid and Hematologic Malignancies

ArticleYear
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
    Blood, 2022, 09-15, Volume: 140, Issue:11

    Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Hematologic Neoplasms; Hemorrhage; Huma

2022
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri
    Trials, 2019, Oct-15, Volume: 20, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Australia; Double-Blind

2019

Other Studies

2 other studies available for tranexamic acid and Hematologic Malignancies

ArticleYear
Tranexamic acid as a stopgap for low platelets?
    Blood, 2022, 09-15, Volume: 140, Issue:11

    Topics: Antifibrinolytic Agents; Blood Platelets; Hematologic Neoplasms; Humans; Tranexamic Acid

2022
Use of tranexamic acid in gastrointestinal bleeding and patients with haematological malignancies.
    ANZ journal of surgery, 2020, Volume: 90, Issue:4

    Topics: Antifibrinolytic Agents; Gastrointestinal Hemorrhage; Hematologic Neoplasms; Humans; Tranexamic Acid

2020